Evaxion scrapped its next-gen solid tumor vaccine program EVX-03 and redirected resources toward a Duke-partnered brain cancer candidate, tightening focus after EVX-03 failed to progress into planned clinical testing. The Danish biotech confirmed the discontinuation as portfolio management in its latest disclosures. Evaxion said learnings from EVX-03 informed two higher-priority programs: EVX-05, an off-the-shelf glioblastoma therapeutic vaccine, and EVX-04 for acute myeloid leukemia, both in earlier stages. EVX-05 is built around endogenous retrovirus-derived antigens, with Duke University School of Medicine collaboration led by Mustafa Khasraw for phase 1 planning. For the vaccine field, the move underscores how platform-level progress can be redirected when a lead clinical path stalls, while partnerships and antigen selection strategies remain in focus for speed-to-clinic.